Destiny Pharma (DEST) Issues Quarterly Earnings Results, Misses Estimates By $0.10 EPS

Destiny Pharma (LON:DEST) released its quarterly earnings data on Thursday. The company reported GBX (8.40) (($0.12)) earnings per share (EPS) for the quarter, missing the consensus estimate of GBX (8.30) (($0.12)) by GBX (0.10) ($0.00), Bloomberg Earnings reports.

LON DEST opened at GBX 129 ($1.82) on Friday. Destiny Pharma has a 1-year low of GBX 111 ($1.57) and a 1-year high of GBX 235 ($3.32).

Separately, FinnCap reissued a “corporate” rating and set a GBX 250 ($3.53) price target on shares of Destiny Pharma in a report on Thursday.



TRADEMARK VIOLATION NOTICE: This story was originally posted by Dakota Financial News and is the property of of Dakota Financial News. If you are reading this story on another publication, it was copied illegally and republished in violation of U.S. and international copyright laws. The legal version of this story can be viewed at https://dakotafinancialnews.com/2018/04/14/destiny-pharma-dest-issues-quarterly-earnings-results-misses-estimates-by-0-10-eps.html.

Destiny Pharma Company Profile

Destiny Pharma plc, a biotechnology company, focuses on the development of novel medicines for the treatment of infectious diseases in the United Kingdom. It is involved in developing XF-73 Nasal for the treatment of post-surgical staphylococcal infections; XF-73 Throat for the treatment of staphylococcal hospital/ventilator pneumonia infections; XF-70 Dermal for the treatment of skin burn wound infections of antibiotic resistant bacteria; and XF-70 Lung for the treatment of bacterial biofilm-associated infections.

Receive News & Ratings for Destiny Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Destiny Pharma and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply